Deutsche Bank raised the firm’s price target on Cellebrite to $9 from $6.50 and keeps a Buy rating on the shares. The company showed strong execution in Q2 and raised its outlook across the board, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLBT:
- Cellebrite appoints Thomas Hogan as chairman of the board
- Cellebrite raises FY23 revenue to $310M-$320M from $305M-$315M
- Cellebrite reports Q2 EPS 5c, consensus 2c
- Cellebrite Announces Second-Quarter 2023 Results
- Cellebrite Wins Five Forensic Focus 4:cast Awards, Reinforcing Standing as Digital Intelligence Leader